InVivo opens new development laboratory and manufacturing facility

InVivo Therapeutics Corporation ("InVivo Therapeutics"), a company focused on the development of groundbreaking technologies for the treatment of spinal cord injuries (SCI), today announced that it has signed a lease to open its first manufacturing and development facility in Medford, Massachusetts. The company expects to use this new facility to scale up the manufacturing process for its lead product candidate, a novel biocompatible polymer scaffolding device used to treat acute open-wound SCI.

“This new development laboratory and manufacturing facility represents a critical component of our strategy and brings us one step closer to launching our first human clinical trial. We will put the space to use immediately while working toward securing a larger, commercial-scale cGMP facility here in the Commonwealth of Massachusetts.”

Frank Reynolds, CEO of InVivo Therapeutics, said, "This new development laboratory and manufacturing facility represents a critical component of our strategy and brings us one step closer to launching our first human clinical trial. We will put the space to use immediately while working toward securing a larger, commercial-scale cGMP facility here in the Commonwealth of Massachusetts."

InVivo expects to commence a human clinical trial of its novel biocompatible polymer scaffolding device upon U.S. Food and Drug Administration (FDA) clearance of an investigational device exemption (IDE) application.